Evidence map›Paper›PMID 12117931›Full record

ArticleInfection and immunity2002

Pathogenesis of pneumococcal pneumonia in cyclophosphamide-induced leukopenia in mice.

Erjian Wang, Marie Simard, Nathalie Ouellet, Yves Bergeron, Denis Beauchamp, Michel G Bergeron

Open access · greenAbstract read
In one paragraph

Article in Infection and immunity, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 38 citations in OpenAlex.

  1. Trial
  2. Neutrophil reduction attenuates the severity of lung injury in the early phase of pneumococcal pneumonia in mice.American journal of physiology. Lung cellular and molecular physiology · 2024
    Article
  3. Article
  4. Article
  5. Review
  6. Mouse Models and Tools for theFrontiers in immunology · 2019
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Erjian WangInfectious Diseases Research Center, Laval University, Quebec City, Canada G1V 4G2.
Marie Simard
Nathalie Ouellet
Yves Bergeron
Denis Beauchamp
Michel G Bergeron
Université Laval · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Streptococcus pneumoniae pneumonia frequently occurs in leukopenic hosts, and most patients subsequently develop lung injury and septicemia. However, few correlations have been made so far between microbial growth, inflammation, and histopathology of pneumonia in specific leukopenic states. In the present study, the pathogenesis of pneumococcal pneumonia was investigated in mice rendered leukopenic by the immunosuppressor antineoplastic drug cyclophosphamide. Compared to the immunocompetent state, cyclophosphamide-induced leukopenia did not hamper interleukin-1 (IL-1), IL-6, macrophage inflammatory protein-1 (MIP-1), MIP-2, and monocyte chemotactic protein-1 secretion in infected lungs. Leukopenia did not facilitate bacterial dissemination into the bloodstream despite enhanced bacterial proliferation into lung tissues. Pulmonary capillary permeability and edema as well as lung injury were enhanced in leukopenic mice despite the absence of neutrophilic and monocytic infiltration into their lungs, suggesting an important role for bacterial virulence factors and making obvious the fact that neutrophils are ultimately not required for lung injury in this model. Scanning and transmission electron microscopy revealed extensive disruption of alveolar epithelium and a defect in surfactant production, which were associated with alveolar collapse, hemorrhage, and fibrin deposits in alveoli. These results contrast with those observed in immunocompetent animals and indicate that leukopenic hosts suffering from pneumococcal pneumonia are at a higher risk of developing diffuse alveolar damage.

Indexed as

AnimalsAntineoplastic Agents, AlkylatingCapillary PermeabilityCell MovementChemokine CCL2Chemokine CCL4Chemokine CXCL2ChemokinesCyclophosphamideDisease Models, AnimalEdemaInterleukin-1Interleukin-6LeukocytesLeukopeniaLungAntineoplastic Agents, AlkylatingChemokine CCL2Chemokine CCL4Chemokine CXCL2ChemokinesCxcl2 protein, mouseCyclophosphamideInterleukin-1Interleukin-6Macrophage Inflammatory Proteins

Identifiers

PMID12117931
PMCPMC128150
OpenAlexW2012427838

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.